Evidence map›Paper›PMID 34989873›Full record

ArticleBioprocess and biosystems engineering2022

Continuous background correction of refractive index signal to improve monoclonal antibody concentration monitoring during UF/DF and SPTFF operations.

Thaddaeus A Webster, Kelley Turner, Caitlin DuBois, Ryan MacDougall, Carrie Mason

Abstract read
PubMed Publisher
In one paragraph

Article in Bioprocess and biosystems engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Thaddaeus A WebsterLonza Biologics Inc., 101 International Dr, Portsmouth, NH, 03801, USA. thaddaeus.webster@lonza.com.ORCID http://orcid.org/0000-0002-2923-4711
Kelley TurnerLonza Biologics Inc., 101 International Dr, Portsmouth, NH, 03801, USA.
Caitlin DuBoisLonza Biologics Inc., 101 International Dr, Portsmouth, NH, 03801, USA.
Ryan MacDougallLonza Biologics Inc., 101 International Dr, Portsmouth, NH, 03801, USA.
Carrie MasonLonza Biologics Inc., 101 International Dr, Portsmouth, NH, 03801, USA.
Lonza (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inline refractive index (RI) has the potential for monitoring protein concentration during final bulk concentration. While useful for monitoring and controlling product concentration, RI is sensitive to the respective background buffer being used for processing. This raises concerns around variations in buffer preparations, and during diafiltration where the buffer background is a mixture of different buffers during exchange. This study evaluated whether the use of a RI probe in the permeate line could facilitate continuous background subtraction (dual RI) and improve concentration monitoring during ultrafiltration/diafiltration and single pass TFF concentration for IgG1 and IgG4 antibodies. The proposed dual RI strategy yielded reductions in % error compared to the use of a single refractive index estimate from the retentate line (6.18% vs 8.63% for IgG4 and 2.65% vs 8.85% for IgG1) during traditional ultrafiltration/diafiltration. The improvement in IgG estimates were best during diafiltration where the continuous background subtraction of the permeate RI-enabled continuous monitoring of antibody material without knowledge of what the background buffer was compared to the use of a single RI estimate (6.47% vs 10.79% for IgG4 and 3.29% vs 19.59% for IgG1). In contrast minimal improvement to accuracy was obtained when using SPTFF as a concentration step. The ability to monitor product concentration changes via the proposed dual RI approach removes the need for complex calibrations, minimal worry about changing buffer backgrounds during diafiltration, and could enable better process control during product concentration in the cGMP manufacture of biologics.

Indexed as

Antibodies, MonoclonalRefractometryUltrafiltrationAntibodies, MonoclonalContinuous product concentration monitoringDual RI

Identifiers

PMID34989873
OpenAlexW4206460126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.